Forsta AP Fonden cut its holdings in Stryker Co. (NYSE:SYK) by 4.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 112,153 shares of the medical technology company’s stock after selling 5,300 shares during the period. Forsta AP Fonden’s holdings in Stryker were worth $18,938,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Centaurus Financial Inc. acquired a new position in shares of Stryker in the 2nd quarter valued at about $110,000. Kaizen Advisory LLC boosted its holdings in shares of Stryker by 142.6% in the 2nd quarter. Kaizen Advisory LLC now owns 752 shares of the medical technology company’s stock valued at $127,000 after buying an additional 442 shares during the period. NumerixS Investment Technologies Inc acquired a new position in shares of Stryker in the 2nd quarter valued at about $135,000. CX Institutional acquired a new position in shares of Stryker in the 2nd quarter valued at about $133,000. Finally, Bruderman Asset Management LLC acquired a new position in shares of Stryker in the 1st quarter valued at about $152,000. 75.08% of the stock is owned by institutional investors and hedge funds.

In other Stryker news, VP Katherine Ann Owen sold 37,866 shares of the business’s stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $166.84, for a total transaction of $6,317,563.44. Following the sale, the vice president now directly owns 11,367 shares in the company, valued at approximately $1,896,470.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 7.40% of the stock is currently owned by insiders.

Several research firms have recently commented on SYK. ValuEngine raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, June 26th. Sanford C. Bernstein began coverage on shares of Stryker in a report on Wednesday, June 27th. They issued a “market perform” rating and a $177.00 price target for the company. Zacks Investment Research raised shares of Stryker from a “hold” rating to a “buy” rating and set a $191.00 price target for the company in a report on Wednesday, June 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker in a report on Tuesday. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $185.00 price target on shares of Stryker in a report on Wednesday, July 25th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. Stryker has a consensus rating of “Buy” and a consensus price target of $178.33.

Shares of NYSE:SYK opened at $173.07 on Friday. The stock has a market capitalization of $64.24 billion, a P/E ratio of 26.67, a PEG ratio of 2.41 and a beta of 0.59. Stryker Co. has a fifty-two week low of $138.94 and a fifty-two week high of $179.84. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.15 and a current ratio of 1.83.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, July 24th. The medical technology company reported $1.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.73 by $0.03. The firm had revenue of $3.32 billion for the quarter, compared to the consensus estimate of $3.31 billion. Stryker had a net margin of 8.28% and a return on equity of 26.93%. Stryker’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $1.53 EPS. research analysts expect that Stryker Co. will post 7.25 earnings per share for the current fiscal year.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Article: What is a Stop Order?

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.